» Articles » PMID: 12093005

CD4+ CD25+ Suppressor T Cells: More Questions Than Answers

Overview
Journal Nat Rev Immunol
Date 2002 Jul 3
PMID 12093005
Citations 570
Authors
Affiliations
Soon will be listed here.
Abstract

Several mechanisms control discrimination between self and non-self, including the thymic deletion of autoreactive T cells and the induction of anergy in the periphery. In addition to these passive mechanisms, evidence has accumulated for the active suppression of autoreactivity by a population of regulatory or suppressor T cells that co-express CD4 and CD25 (the interleukin-2 receptor alpha-chain). CD4+ CD25+ T cells are powerful inhibitors of T-cell activation both in vivo and in vitro. The enhancement of suppressor-cell function might prove useful for the treatment of immune-mediated diseases, whereas the downregulation of these cells might be beneficial for the enhancement of the immunogenicity of vaccines that are specific for tumour antigens.

Citing Articles

Knowledge landscape of Treg research in breast cancer: a bibliometric and visual analysis.

Wu Z, Zhang Y, Gong Y, Hu J Front Oncol. 2024; 14:1448714.

PMID: 39664195 PMC: 11631855. DOI: 10.3389/fonc.2024.1448714.


Integrative analysis of single-cell RNA-seq and gut microbiome metabarcoding data elucidates macrophage dysfunction in mice with DSS-induced ulcerative colitis.

Hong D, Kim H, Yang W, Yoon C, Kim M, Yang C Commun Biol. 2024; 7(1):731.

PMID: 38879692 PMC: 11180211. DOI: 10.1038/s42003-024-06409-w.


Regulatory CD4 T cells: permanent or temporary suppressors of immunity.

LeGuern C, Markmann J Front Immunol. 2024; 15:1293892.

PMID: 38404584 PMC: 10890821. DOI: 10.3389/fimmu.2024.1293892.


Targeting T regulatory (T) cells in immunotherapy-resistant cancers.

Spiliopoulou P, Kaur P, Hammett T, Di Conza G, Lahn M Cancer Drug Resist. 2024; 7:2.

PMID: 38318526 PMC: 10838381. DOI: 10.20517/cdr.2023.46.


Drug conjugates for targeting regulatory T cells in the tumor microenvironment: guided missiles for cancer treatment.

Yang J, Bae H Exp Mol Med. 2023; 55(9):1996-2004.

PMID: 37653036 PMC: 10545761. DOI: 10.1038/s12276-023-01080-3.